Современные гормональные контрацептивы и масса тела
- Авторы: Доброхотова ЮЭ1
-
Учреждения:
- РГМУ
- Выпуск: Том 10, № 5 (2008)
- Страницы: 15-18
- Раздел: Статьи
- URL: https://ogarev-online.ru/2079-5831/article/view/27944
- ID: 27944
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Ю Э Доброхотова
РГМУКафедра акушерства и гинекологии московского факультета с курсом ФУВ
Список литературы
- Kopelman P, Stock M. Clinical Obesity, 1998.
- Bjorkelund C et al. Reproductive history in relation to relative weight and fat distribution. Int J Obes 1996; 20 (3): 213–9.
- Samsioe G. Oral contraceptives and the cardiovascular issue. In: The Pill; Parthenon Publishing Group; London; 1990; 43–5.
- Fortney J, Harper J. Oral contraceptives and expectancy. Stud Fam Planning 1986; 17: 117–25.
- Rosenberg M. Meyers A, Roy V. Efficacy, cycle control, and side effects of low - and lower - dose oral contraceptives: a randomized trial of 20 microgram and 35 microgram preparations. Contraception 1999; 6: 321–9.
- Phillips N, Duffy T. One hour glucose tolerance in relation to use of oral contraceptive drugs. Am J Obst Gyn 1973; 116: 91–100.
- Risser W.L, Gefter L.R. Weight change in adolescents who used hormonal contraception. J Adolesc Health 1999; 24 (6): 433–6.
- Rosenbaum H. Resent developments in the composition of oral contraceptives. In: The Pill; Parthenon Publishing Group; London; 1990; 53–9.
- Moses L.E. The influence of a secvential oral contraceptiveon the carbohydrate metabolism. Boston; Exc Medical International Congress Series 224, 1970.
- Goldzieher J.W, Fotherb K.Y. Pharmacology of the Contraceptive Steroids. Raven Press, New York, 1994; 354–7.
- Berga S.L. Metabolic and endocrine effect of the desogestrel - containing oral contraceptive Mircette. Am J Obst Gyn 1998; 179 (1): S9–17.
- van der Mooren M.J, Klipping C.A. comparative study of the effect of gestodene 60 mcg/EE 15 mcg.and desogestrel 150 mcg/EE 20 mcg on hemostatic balance, blod lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 1999; 4 (Suppl. 2): 27–35.
- Eck L.H, Bennet A.G. Differenctes in macronutrient selections in users and nonusers an oral contraceptive. Am J Clin Nutr 1997; 65 (2): 419–24.
- Litchfield R.E, Grunvald K.K. Oral contraceptives and fat patterning in young adult women. Hum Biol 1988; 60 (5): 793–800.
- van den Heuvel M.W et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72: 168–74
- Guillbaud J. Contraception. Churchhill Livingstone; London; 1993; 156–268.
- Gallo M.F et al. Combination estrogen - progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 2004; 103 (2): 359–73.
- Lammers P, Op ten Berg M. Phase III Clinical trial with a new oral contraceptive containing 150 mcg desogestrel and 20 mcg ethynilestradiol. ACT Obstetr Gynecol Scand 1991; 70: 497–500.
- Lav Тn. et al. Effect on bleeding patterns following the use of a low dose desogestrel - containing oral contraceptive. Eur J Contracept Reprod Health Care 2002; 7 (suppl. 1): 86.
- Milsom I et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 mg ethinylestradiol and 3 mg drospirenone. Human Reproduction 2006; 21 (9): 2304–11.
- Keam S.J, Wagstaff A.J. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat Endocrinol 2003; 2: 49–70.
Дополнительные файлы
